KLK3 and Familial prostate cancer: Many companies are now assessing multi-omic approaches by combining clinical information in their protocols, such as natural risk factors (e.g., age), specific risk factors (e.g., common biomarkers; for example, prostate specific antigen, PSA, for prostate cancer), and imaging results (e.g., computed tomography, CT; or magnetic resonance imaging, MRI), with their genetic cancer-related biomarkers (e.g., ctDNA; messenger RNA, mRNA; etc.).